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Reply. We read with a considerable attention the comments of
Lees et al, relative to potential side effects that might occur in
the digestive tract while manipulating the Hedgehog (Hh) sig-
naling pathway. Considering these statements, we would like to
underline some parallel issues, with likely consequences on
cancer therapeutic strategy.
There is first a crucial need of more fundamental studies to
reasonably understand the scope of Hh and PPAR actions in
the gastrointestinal (GI) tract, particularly with respect to the
risk of cancer development. The correspondence by Lees et al
indeed underscores how Hh inhibition is on the one hand
proposed to potentially treat a variety of cancer, including
colon cancer, while on the other hand potentially promoting
colon carcinogenesis.1 Similar discrepancies are observed con-
cerning the role of PPAR in the appearance and growth of
cancer in the GI tract, with evidence either for protumori-
genic2– 6 or antitumorigenic activity.7–9 The PPAR-mediated
down-regulation of Ihh expression, which favors Paneth cell
maturation, might also be negatively considered because of the
presence of Paneth cells in familial adenomatous polyposis
dysplasia, as well as in the corresponding mouse model.10,11 In
contrast, it might also be interpreted as one mechanism by
which activated PPAR favors cell differentiation and may
protect from GI tumorigenesis.
The second and related issue is that both Hh and PPAR
pathways are active in a broad range of tissues and organs. For
each tissue, within the GI tract and outside this organ, they
might trigger different responses depending on other interfer-
ing pathways that are also active (eg, Wnt, Notch, Akt). For both
pathways, the use of systemic agents are presently considered,
in cancer, tissue repair and inflammation for Hh, and to treat
metabolic disorders for PPAR.12 As highlighted in the corre-
spondence by Lees et al, it seems indeed very important to raise
a word of caution, proposing a careful and recurrent examina-
tion of the GI tract response to these drugs, when given in a
non–GI-related pathology. Alternately, manipulating either Hh
or PPAR signaling in the context of tumor, regardless of its
localization, should rather be considered in the context of
site-specific drug delivery systems, such as with antibody– drug
conjugates specifically targeting epitopes present at the cancer
cell surface (reviewed Schrama et al13).
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Correction
Mori Y, Cai K, Cheng Y, Wang S, Paun B, Hamilton JP, Jin Z, Sato F, Berki AT, Kan T, Ito T, Mantzur C, Abraham JM,
Meltzer SJ. A genome-wide search identifies epigenetic silencing of Somatostatin, Tachykinin-1, and 5 other genes in colon
cancer. Gastroenterology 2006;131:797– 808.
The third paragraph in the Results section should have read as follows:
In support of our approach, 6 of these genes had been reported to undergo promoter hypermethylation and mRNA
down-regulation in human cancers in the literature: RUNX3, HLTF/SMARCA3, RAB32, AKAP12, CAV1, and RRAD/
REM3. RUNX3, HLTF/SMARCA3, and RAB32 were hypermethylated in primary colon cancers, whereas AKAP12,
CAV1, and RRAD/REM3 were hypermethylated in non-colonic cancers.6,8 –10,12,13
Answer to the Clinical Challenges and Images in GI Question: Image 1 (page 1379):
Yersinia enterocolitica Mesenteric Adenitis and Terminal Ileitis
The presentation and clinical studies supported a differential diagnosis of malignancy, Crohn’s disease, as well as infectious
mesenteric adenitis. Histological findings from colonic biopsies revealed severe acute colitis with neutrophils infiltrations, acute
ulceration, and necrosis. Stool cultures yielded growth of Yersinia enterocolitica. The patient was treated with antibiotics based on
sensitivity test. His symptoms resolved promptly with medical therapy alone. Twenty-four days later, follow-up colonoscopy showed
complete healing of the ulcer. The patient recovered completely and was discharged without surgery. Two months later, abdominal
CT showed a clear regression of enlarged mass. Retrospectively, the CT findings were compatible with mesenteric adenitis.
Infection with Y enterocolitica is usually a benign, self-limited disorder characterized by fever, diarrhea, abdominal pain, mesenteric
adenitis, erythema nodosum, or other immunologic manifestations. Emergency intestinal resections have been performed in some
patients, however, and some have died of fulminant disease. Yersinia septicemia can occur during acute infection, particularly infants
and those with impaired immune defenses or iron-overload states.1,2 Y enterocolitica usually invades via Peyer’s patches, causing
microabscesses, and ulceration of the overlying epithelium. The organism commonly involves the terminal ileum and can invade
mesenteric nodes.3 Mesenteric adenities, which is the most common clinical manifestation, causes a pseudoappendicular syndrome.
However, there have been very few reports of Yersinia infection presenting as an abdominal mass.4 Although rare, as in our case, it
can present with an abdominal mass caused by pathologic enlargement of one or more of the mesenteric lymph nodes in the
ileocecal region. Yersinia infection should be considered in patients with a right lower abdominal mass.
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